{ "week": "2026-W33", "label": "Week 33 \u2014 August 16\u201322, 2026", "week_start": "2026-08-16", "generated": "2026-08-17", "stats": { "total_entries": 1067, "new_this_week": 65, "compounds_represented": 8 }, "by_compound": { "psilocybin": [ { "id": "11a2c1906c3202f71e440233329a968b8e82023c806fd79d77c4b762e7f62578", "title": "Subacute and long-term changes in cognitive functioning after administration of classic psychedelics, MDMA and ketamine: A systematic review of clinical and preclinical evidence.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-14", "abstract": "Psychedelic agents induce a window of heightened neuroplasticity that extends beyond acute intoxication, during which neural circuits are more amenable to change. This period may facilitate changes in cognition relevant to the treatment of psychiatric disorders.\u2026", "outcome_summary": null, "doi": "10.1016/j.neubiorev.2026.106911", "url": "https://pubmed.ncbi.nlm.nih.gov/42600962/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Review of cognitive changes after psychedelics and ketamine.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "74fc8e557f053e1d0aa5cf9c5d959d6a461048b42120574e7320309f77e97589", "title": "Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-13", "abstract": "Psychedelic microdosing has gained increasing popularity for enhancing mood and cognition, yet its effects on psychological outcomes in healthy adults remain unclear.\u2026", "outcome_summary": null, "doi": "10.1007/s40263-026-01325-5", "url": "https://pubmed.ncbi.nlm.nih.gov/42593636/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Systematic review of psychedelic microdosing on psychological outcomes.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "86e2d508d69ff27148d5fd866e38348f3151c4f35e9edfeb40bf73a78faaaee2", "title": "Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from Jamaica.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "We report two case studies that examine the therapeutic potential of structured psilocybin-containing mushroom biomass regimens administered within a clinical framework, evaluating their impact on mental health outcomes as well as associated somatic symptoms.\u2026", "outcome_summary": null, "doi": "10.3389/fpsyt.2026.1876189", "url": "https://pubmed.ncbi.nlm.nih.gov/42591237/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psilocybin for psychological and somatic improvements in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "cda4e126940e9e5b03b40117104f993eb474ed3f67f512debca7552d3be35af8", "title": "The mechanism debate in psilocybin therapy for depression.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-01", "abstract": null, "outcome_summary": null, "doi": "10.1016/j.ebiom.2026.106440", "url": "https://pubmed.ncbi.nlm.nih.gov/42586623/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Mechanism of action for psilocybin in depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "1a5307f2708161f0d4b06261b8ffca63b55f961cb9bda7b5e6f1e7d9e74f24cb", "title": "Psychedelics and astrocytes: a hypothesis-driven perspective on neuro-glial integration, network plasticity, and neuroimmune reprogramming.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-11", "abstract": "Psychedelics, including psilocybin, lysergic acid diethylamide (LSD) and related psychoplastogens, have re-emerged as powerful modulators of brain function with therapeutic potential across a broad range of neuropsychiatric disorders.\u2026", "outcome_summary": null, "doi": "10.1038/s41380-026-03816-9", "url": "https://pubmed.ncbi.nlm.nih.gov/42581074/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Neuro-glial integration and neuroimmune reprogramming in neuropsychiatric disorders.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "dcb4105534382c7e61847468a1bacce98ec6cabadbe0824928226e5284cf3844", "title": "Effects of naturalistic psychedelic use on executive functioning: An online survey of lifetime history and recent use in university students.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-08-11", "abstract": "Classic psychedelics such as psilocybin and LSD have shown therapeutic potential for a variety of substance use and mental health disorders. Emerging evidence suggests that psychedelics may enhance cognitive function post-acutely, potentially contributing to their therapeutic effects.\u2026", "outcome_summary": null, "doi": "10.1016/j.pnpbp.2026.111888", "url": "https://pubmed.ncbi.nlm.nih.gov/42580581/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Naturalistic use survey in university students", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "56042db93cf3033a24a950999a0d0423e969fd05f3190faabdd708246f91c168", "title": "Real-World Psilocybin Therapy for Treatment-Resistant Depression: A Retrospective Observational Study.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-01", "abstract": "Psilocybin has demonstrated promising antidepressant effects in depression and treatment-resistant depression (TRD) in controlled clinical trials. However, its effectiveness and safety in real-world therapeutic settings remain largely unknown.\u2026", "outcome_summary": null, "doi": "10.1016/j.lanepe.2026.101719", "url": "https://pubmed.ncbi.nlm.nih.gov/42577282/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Observational study of psilocybin for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "ec622e58d160ad48d65a516686fc51be54cdc0986d2b544c539d828f4881fa2e", "title": "An Open-Label Trial Protocol to Test Menstrual Cycle Effects and Tolerance to Low-Dose Psilocybin in Healthy Menstruating Persons.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-10", "abstract": "Research on the therapeutic benefits of psychedelics, particularly psilocybin, is becoming increasingly popular. Unfortunately, most psychedelic research overlooks the menstrual cycle as a biological variable, raising concerns about the safety and efficacy of findings for individuals who menstruate.\u2026", "outcome_summary": null, "doi": "10.1159/pha/aejag002", "url": "https://pubmed.ncbi.nlm.nih.gov/42574302/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Healthy volunteers, psilocybin, menstrual cycle effects, tolerance.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "a5a6f1196c8ae1d7547fe6cff85741f3502076c4880a0dd118312ef931c5a352", "title": "'So many relationships in the room': Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "anxiety", "sample_size": null, "status": "published", "date": "2026-08-10", "abstract": "Psychedelic-assisted therapy (PAT) frequently utilises a \"cotherapy\" model, in which two therapists jointly support participants throughout dosing and psychotherapy sessions. While common in clinical trials, participant experiences of cotherapy remain underexplored.\u2026", "outcome_summary": null, "doi": "10.1111/papt.70098", "url": "https://pubmed.ncbi.nlm.nih.gov/42572818/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Participant perspectives on co-therapy in psychedelic assisted therapy.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "7e986c2fa42f64d87bad7322b23eefa25f4b32d84930909f6bbd1d744d3e6a3e", "title": "Psilocybin Therapy for Methamphetamine Use Disorder and HIV", "compound": "psilocybin", "type": "phase_2", "institution": "Nicky Mehtani, MD, MPH", "condition": "other", "sample_size": 30, "status": "recruiting", "date": "2026-11-01", "abstract": "The goal of this clinical trial is to learn whether it is possible to use psilocybin in combination with motivational support therapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in people with HIV who are seeking to stop using methamphetamine.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07756736", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psilocybin for methamphetamine use disorder in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "42e29721f7273baa9670766b9fa6d83459e5fa52c881ddb59c14398b497847fc", "title": "Psilocybin With Intracranial Neural Sensing", "compound": "psilocybin", "type": "phase_1", "institution": "Joshua Woolley, MD, PhD", "condition": "other", "sample_size": 20, "status": "recruiting", "date": "2025-06-01", "abstract": "This is an open-label, single-arm, pilot study exploring the neural, sensory, and cognitive effects of a single, medium dose of psilocybin in patients with chronic pain who already have implanted sensing-capable deep brain stimulation (DBS) devices.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06919640", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psilocybin for chronic pain in a human study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "9264f7f4825c88575471b7fa44ee318f26009285d00a0c4141518de419318c08", "title": "Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers", "compound": "psilocybin", "type": "phase_1", "institution": "University of Nebraska", "condition": "other", "sample_size": 24, "status": "active", "date": "2023-04-10", "abstract": "The primary objective of this study is to evaluate the ability to recruit and retain participants, and to successfully conduct a psilocybin-based protocol, for a study of the treatment of distress related to stage IV or inoperable gastrointestinal cancers.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05220046", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psilocybin for psychological distress in advanced cancer patients.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "7742c11ad0e9fbfaed7bd77a805a3ec9534932331d89f6a197fa9e93020f0ea0", "title": "Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies", "compound": "psilocybin", "type": "phase_2", "institution": "University of New Mexico", "condition": "depression", "sample_size": 150, "status": "recruiting", "date": "2026-08-31", "abstract": "PRE-EMPT will assemble a cohort of 150 participants from three populations (low risk, intermediate risk, and high risk for self-harm).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07745569", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Assesses behavioral risk and response to psychedelic therapies.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "f74e18e6df4c151056a9461b01a6cbcb803aec16e5f2b4745dee12a7848f75d3", "title": "Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder", "compound": "psilocybin", "type": "phase_2", "institution": "Psyence Australia Pty Ltd", "condition": "anxiety", "sample_size": 87, "status": "recruiting", "date": "2025-10-01", "abstract": "This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for?\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07072728", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psilocybin for adjustment disorder in cancer patients.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "5f1ec9ad94b73e76b5db7678fd4361958e7f61dc5bee45650893d1b986086697", "title": "The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density", "compound": "psilocybin", "type": "phase_2", "institution": "Section for Affective Disorders; Northern Stockholm Psychiatry", "condition": "depression", "sample_size": 35, "status": "completed", "date": "2021-01-01", "abstract": "PROTOCOL SYNOPSIS Title The effect of psilocybin on Major depressive disorder (MDD) symptom severity and synaptic density - a single dose randomized, double blind, placebo-controlled phase 2b positron emission tomography study Study Code PSIPET Name of Sponsor SLSO Organisationsnr: 232100-0016 Sponsor representative: Andreas Carlborg Norra Stockholms Psykiatri V\u00e5rdv\u00e4gen 3 112 19 Stockholm Sweden Medical Monitor Inspira Medical AB Phase of Study Phase 2b Sample Size 30 randomized Name of Investigational Product (IP) Psilocybin, 3-\\[2-(dimethylamino)ethyl\\]-1H-indol-4-yl\\] dihydrogen phosphate Name of Active Placebo Niacin EudraCT 2020-002790-94 Description of IP and Active Placebo PSIPET Protocol 5 200821 Page 14 Study Intervention Name: Psilocybin (active drug product) Niacin (active placebo product) Dosage formulation: One active capsule contains 25 mg of psilocybin One active placebo capsule contains 100 mg of niacin Capsule: Size 2 hydroxypropyl methylcellulose (HPMC), opaque Size 2 HPMC, opaque Unit dose strength: 25 mg 100 mg Route of Administration: Oral (solid dose) Oral (solid dose) Dosing instructions: One capsule administered with water One capsule administered with water Packaging and Labeling: Study Intervention will be provided in a high-density polyethylene (HDPE) bottle.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04630964", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psilocybin for Major Depressive Disorder (MDD) symptom severity.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "aba18fa33c307a7b75b39459ec047f81377e58797f031c17a1dc94484aa939cb", "title": "Psychopharmacology of Psilocybin in Cancer Patients", "compound": "psilocybin", "type": "phase_2", "institution": "Johns Hopkins University", "condition": "depression", "sample_size": 56, "status": "completed", "date": "2007-04-01", "abstract": "This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT00465595", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psilocybin for psychological effects in cancer patients.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "1dac0d7e44e7b99931b97290a027fbee5c39c52b66f1a56a2d8366ffca3f61a9", "title": "Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)", "compound": "psilocybin", "type": "phase_2", "institution": "Centre for Addiction and Mental Health", "condition": "depression", "sample_size": 16, "status": "recruiting", "date": "2025-04-01", "abstract": "Psilocybin, the chemical component of \"magic mushrooms\", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06518720", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psilocybin for chronic neuropathic pain and depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "f421c7a77c38a3154d58edbf85115d5e033057d2242abb9ad51e53d0ee8b6596", "title": "Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD", "compound": "psilocybin", "type": "phase_3", "institution": "COMPASS Pathways", "condition": "depression", "sample_size": 572, "status": "active", "date": "2023-02-14", "abstract": "Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05711940", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "COMP360 for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "7a5426745a1a5f72aae709bd32f33f6e8dfa7e7bbed8ebeb47a148777c4a4692", "title": "Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial", "compound": "psilocybin", "type": "phase_2", "institution": "National Health Service (NHS)", "condition": "depression", "sample_size": null, "status": "completed", "date": "2026-08-06", "abstract": "Reprints and permissions ## About this article Check for updates. Verify currency and authenticity via CrossMark ### Cite this article Rucker, J.J., Mantingh, T., Kerr-Gaffney, J. et al.\u2026", "outcome_summary": "A randomized controlled trial examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a two-arm, double-blind, randomized, placebo-controlled feasibility trial with 6 weeks of follow-up. Participants met DSM-5 criteria for major depressive disorder and had an inadequate response to prior treatments.", "doi": "10.1038/s41591-026-04541-0", "url": "https://www.nature.com/articles/s41591-026-04541-0", "source": "General News", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "5e672cd81055e1edead75b6067242433116374e2b8427e1fb9ff012bc5cb9067", "title": "\u2019Shrooms Lead the Pack in Psychedelic Medicine, but Rollout Is Bumpy", "compound": "psilocybin", "type": "news", "institution": "Compass Pathways", "condition": "depression", "sample_size": null, "status": "other", "date": "2026-01-13", "abstract": "Health|\u2019Shrooms Lead the Pack in Psychedelic Medicine, but Rollout Is Bumpy. https://www.nytimes.com/2026/01/13/health/shrooms-lead-the-pack-in-psychedelic-medicine-but-rollout-is-bumpy.html. When we have confirmed access, the full article content will load.\u2026", "outcome_summary": "Psilocybin-assisted therapy is legal in three states, but access has so far been limited and expensive. The FDA is moving up its review of a psilocybin treatment for severe depression.", "doi": null, "url": "https://www.nytimes.com/2026/01/13/health/shrooms-lead-the-pack-in-psychedelic-medicine-but-rollout-is-bumpy.html", "source": "General News", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psilocybin therapy for depression, legal status, and FDA review.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } } ], "mdma": [ { "id": "a96a2a3f684a7ca72ad256b1304182b3918b5b1f6095eaa8244ac96bcbfaa3a6", "title": "MDMA-AT for PTSD in Young Adults With Childhood Trauma", "compound": "mdma", "type": "phase_2", "institution": "Jenna M. Traynor", "condition": "PTSD", "sample_size": 15, "status": "recruiting", "date": "2026-10-31", "abstract": "This study is testing a new, emerging treatment for young adults (ages 18-26) with Posttraumatic Stress Disorder (PTSD). The treatment is combining the substance, MDMA, with up to three psychotherapy sessions, also known as MDMA-Assisted Therapy (MDMA-AT).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07765693", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "MDMA-AT for PTSD in young adults is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "9ccaa2de2d7e29666d4cf4233256b06915a6180ff6fe74aaa6ec7dd6e966d1cc", "title": "MAPS Responds to Report of Progress for MDMA-Assisted Therapy for PTSD with FDA", "compound": "mdma", "type": "regulatory", "institution": "MAPS", "condition": "PTSD", "sample_size": null, "status": "active", "date": "2026-08-10", "abstract": "

August 10, 2026 \u2014 The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an August 9 report by Psychedelic Alpha indicating that Resilient Pharmaceuticals (formerly MAPS PBC and Lykos Therapeutics) has resubmitted its new drug application (NDA) for MDMA-assisted therapy for PTSD to the U.S.\u2026", "outcome_summary": "MAPS is responding to a report that Resilient Pharmaceuticals has resubmitted its new drug application for MDMA-assisted therapy for PTSD to the FDA, following a Complete Response Letter in August 2024. The resubmission occurs without a new Phase 3 study, and the FDA has recently issued new guidance on psychedelic drug investigations.", "doi": null, "url": "https://maps.org/2026/08/10/maps-responds-to-report-of-progress-for-mdma-assisted-therapy-for-ptsd-with-fda/", "source": "MAPS.org", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "MDMA-assisted therapy for PTSD and FDA regulatory news.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "0e49f7eedee866005edfbed39db4b239294336b4ea01c00e4f57e386975400e9", "title": "Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application", "compound": "mdma", "type": "regulatory", "institution": "Resilient Pharmaceuticals", "condition": "PTSD", "sample_size": null, "status": "active", "date": "2026-08-12", "abstract": "As we reported this week, we also expect Definium Therapeutics to submit an LSD for generalised anxiety disorder (GAD) NDA in the first half of 2027.\u2026", "outcome_summary": "Resilient Pharmaceuticals has resubmitted its MDMA for PTSD new drug application (NDA) to the FDA, nearly two years after its initial rejection. The resubmission includes data from third-party studies and a new Phase I safety trial, addressing FDA's previous concerns about adverse events, durability, and participant screening.", "doi": null, "url": "https://psychedelicalpha.com/news/two-years-after-rejection-resilient-quietly-refiles-mdma-for-ptsd-application", "source": "General News", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "MDMA for PTSD is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } } ], "ketamine": [ { "id": "8d39ac97eee2742e80a73847cf4a78e978386690169d3b6bd392e5de1c4ba172", "title": "Rapid Symptom Reduction Following Intramuscular Ketamine in Refractory Obsessive-Compulsive Disorder: A Case Report.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Obsessive-compulsive disorder (OCD) is a chronic psychiatric condition that frequently presents with comorbid depressive disorders.\u2026", "outcome_summary": null, "doi": "10.1155/crps/6450306", "url": "https://pubmed.ncbi.nlm.nih.gov/42602667/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for refractory OCD, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "21b7a01cfbc4d64afe77a52c096891f485328fc52eea2116d9f5700e19e1b56c", "title": "Intranasal esketamine for ECT-refractory bipolar depression: a case report.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "This is a case report of a 52 year old female with ECT-refractory bipolar depression who was treated with esketamine nasal spray, leading to a noticeable improvement in her depressive symptoms.\u2026", "outcome_summary": null, "doi": "10.3389/fpsyt.2026.1890002", "url": "https://pubmed.ncbi.nlm.nih.gov/42597507/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Esketamine for bipolar depression, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "8fdaabb84cadb9b9d944e1d6cc12081e410cf31460585460ac252352e7cc6426", "title": "The application of esketamine in cancer-related depressive states: attention from mechanisms to clinical translation.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "This article reviews the clinical status and treatment challenges of cancer-related depressive states, clarifies the mechanism of action of esketamine-a novel rapid-acting antidepressant-compares its efficacy with traditional drugs, evaluates safety and tolerability, and summarizes clinical evidence to support clinical practice and research.\u2026", "outcome_summary": null, "doi": "10.3389/fpsyt.2026.1781915", "url": "https://pubmed.ncbi.nlm.nih.gov/42597205/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Esketamine for cancer-related depressive states, clinical translation.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "8ee1a2d4460a08b97422d67c34646f170ee2bc40a7dc40e2f2a86d4a065bf1e9", "title": "Ketamine assisted psychotherapy to reduce chronic neuropathic pain: A mixed-methods randomized pilot trial.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-13", "abstract": "Intravenous ketamine can provide short-term analgesia in chronic neuropathic pain but benefits often wane after treatment. We conducted a randomized pilot trial to assess the feasibility of combining ketamine infusions with psychotherapy to inform future efficacy trials.\u2026", "outcome_summary": null, "doi": "10.1016/j.medj.2026.101259", "url": "https://pubmed.ncbi.nlm.nih.gov/42594864/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for chronic neuropathic pain treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "994fea44c85ac7163e8348a669a9f29c4619f08d4fdcb024a3917674cdf09a6b", "title": "Psychoactive and Neurobiological Effects of Ketamine in Humans: A Scoping Review of Clinical Evidence.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-29", "abstract": "Background/Objectives: Ketamine has attracted interest in psychiatry due to its rapid antidepressant effects, particularly in patients with inadequate response to conventional treatments.\u2026", "outcome_summary": null, "doi": "10.3390/jcm15155922", "url": "https://pubmed.ncbi.nlm.nih.gov/42590024/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Review of ketamine's psychoactive effects for psychiatric treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "af1ac619a17a5e447ed584e82f30d6b4051bb21c82a1f5f2bc5f2f3284a8e502", "title": "Efficacy of intravenous ketamine for neuropathic pain: a systematic review and meta-analysis of randomized clinical trials.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-11", "abstract": "This study evaluated the efficacy of intravenous ketamine for chronic neuropathic pain through a systematic review and meta-analysis of randomized clinical trials.\u2026", "outcome_summary": null, "doi": "10.1080/17581869.2026.2714980", "url": "https://pubmed.ncbi.nlm.nih.gov/42578417/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Systematic review of ketamine for chronic neuropathic pain.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "ce217c24d61adf500633e840e0b0511c19f980ead83805ec56ca9ad1f0b7ee89", "title": "Combined Ketamine and Cognitive-Behavioral Therapy: Leveraging Metaplasticity to Enhance Treatment Outcomes.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-01", "abstract": "Over the past two decades, ketamine has emerged as a rapid-acting antidepressant, especially among patients with treatment-resistant depression.\u2026", "outcome_summary": null, "doi": "10.1176/appi.focus.20260001", "url": "https://pubmed.ncbi.nlm.nih.gov/42576910/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression, combined with CBT.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "9b59f17aa75198a872ad6335cae20a280b526a9a24fb3b251bc3e727b8fe82f9", "title": "Combining TMS and Ketamine for Treatment-Resistant Depression: Clinical Rationale, Current Evidence, and Practical Guidance.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-01", "abstract": null, "outcome_summary": null, "doi": "10.1176/appi.focus.20260014", "url": "https://pubmed.ncbi.nlm.nih.gov/42576884/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression with TMS.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "8923d40bd7de16b7096153e3b2f6be99254103a11ea238676d964412a51b3a4a", "title": "Intravenous Ketamine reduces psychological pain in suicidal inpatients: A secondary analysis of a six-week randomized placebo-controlled trial.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-10", "abstract": "Psychological pain has been conceptualized as an unbearable inner experience and a possible precondition for suicidal ideation. No randomized placebo-controlled study has specifically investigated psychological pain as a treatment target in psychiatric populations.\u2026", "outcome_summary": null, "doi": "10.1016/j.jad.2026.122366", "url": "https://pubmed.ncbi.nlm.nih.gov/42575195/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for suicidal ideation and psychological pain in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "91bf797f6bfb465b79b6ceb804cd38abaf54cdbdba324ef1691e2a413ce5b283", "title": "Preliminary non-randomized clinical trial of subcutaneous esketamine in treatment-resistant depression: Exploring adjunctive effects of ketamine-assisted psychotherapy.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-10", "abstract": "Ketamine is an effective rapid-acting treatment for treatment-resistant depression (TRD), producing antidepressant effects within hours of administration. Because it induces states of heightened neuroplasticity and psychological openness, psychotherapy may enhance its therapeutic effects.\u2026", "outcome_summary": null, "doi": "10.1016/j.jad.2026.122369", "url": "https://pubmed.ncbi.nlm.nih.gov/42575192/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression with psychotherapy.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "8987c4bf3418d4af34dd87df2eb2511e6c7963fdae869214c1f201c10bbd2825", "title": "Discordant signals: How outcome measurement shapes interpretation of ketamine response in treatment-resistant depression.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-10", "abstract": "Depression rating scales capture heterogeneous symptom domains, raising questions about the comparability of treatment response across instruments. This issue is particularly relevant for rapid-acting interventions such as ketamine.\u2026", "outcome_summary": null, "doi": "10.1016/j.jad.2026.122368", "url": "https://pubmed.ncbi.nlm.nih.gov/42575191/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression outcome measurement.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "4d585beacccda77155bf81dd58e6bfd9911ca9c2f3467a240559a8fc8ce0b387", "title": "Adjunctive transcutaneous auricular vagus nerve stimulation following loss of response to maintenance intranasal esketamine in treatment-resistant depression.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-06", "abstract": null, "outcome_summary": null, "doi": "10.1016/j.ajp.2026.105110", "url": "https://pubmed.ncbi.nlm.nih.gov/42574893/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Treatment-resistant depression with intranasal esketamine.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "a061fc1ed064d8e6766d90bdda70b193e7914edee4ee01fbf46f1500d9536ecb", "title": "CAP-Ketamine for Antidepressant Resistant PTSD", "compound": "ketamine", "type": "phase_2", "institution": "VA Office of Research and Development", "condition": "depression", "sample_size": 163, "status": "completed", "date": "2016-04-18", "abstract": "The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02655692", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant PTSD in military and Veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "f1cc2a2869ae94d92c0ab4c6d427be20501d3886ae60f09854208e7b5484e3f0", "title": "Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression", "compound": "ketamine", "type": "phase_2", "institution": "The University of Texas Health Science Center, Houston", "condition": "depression", "sample_size": 1, "status": "completed", "date": "2019-03-04", "abstract": "Postpartum depression is a non-psychotic major or minor depressive episode that occurs during pregnancy or within 12 months of post-partum period.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04011592", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Sub-anesthetic ketamine for postpartum depression is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "386a08b5eb11245ed795c72d4f75982079e5eee57488a63fc110d02f93a3b23f", "title": "Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement", "compound": "ketamine", "type": "phase_2", "institution": "University of California, San Diego", "condition": "addiction", "sample_size": 88, "status": "recruiting", "date": "2026-02-01", "abstract": "The goal of this clinical trial is to examine the usefulness of Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy (KetaMORE) for individuals with opioid use disorder who are receiving medication treatment.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07369089", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant opioid use disorder (OUD).", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "0e8a180e7e554adb57d72f82fbe14178a477f9344a80269add308b4ac644c0ad", "title": "Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment", "compound": "ketamine", "type": "phase_2", "institution": "Icahn School of Medicine at Mount Sinai", "condition": "depression", "sample_size": 15, "status": "active", "date": "2024-11-01", "abstract": "Ketamine is a NMDA-receptor antagonist that promotes synapse formation and has been shown to rapidly improve symptoms in depression.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06069843", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for depression in mild cognitive impairment", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "17ff48ff57d89a6fa877f29f80521c08c93b485b7867a68def1a8489cc21560a", "title": "Randomized Controlled Trial of Ketamine Infusion With Continuous Epidural Infusion for Treatment of Complex Regional Pain Syndrome", "compound": "ketamine", "type": "phase_2", "institution": "Hospital for Special Surgery, New York", "condition": "other", "sample_size": 3, "status": "completed", "date": "2014-03-24", "abstract": "The purpose of this study is to determine whether epidural and ketamine infusions are effective in the treatment of Complex Regional Pain Syndrome (CRPS).", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02094352", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine infusion for chronic pain (CRPS).", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "5651f66da08e3f1aff660f501e7e43a797e7a38f0254418e1fc16bccb8b85394", "title": "The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression", "compound": "ketamine", "type": "phase_2", "institution": "Janssen Research & Development, LLC", "condition": "depression", "sample_size": 29, "status": "completed", "date": "2013-06-01", "abstract": "The purpose of this study is to assess whether the antidepressant effect from intravenous (IV) ketamine treatment can be maintained by minocycline compared to placebo after IV ketamine treatment is stopped.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01809340", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Depression treatment with ketamine and minocycline.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "06dc16a2937611afb4e28019c01aa78a8e5512134f6eeeee7d4925fedacc3f32", "title": "Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression", "compound": "ketamine", "type": "observational", "institution": "Mclean Hospital", "condition": "depression", "sample_size": 60, "status": "completed", "date": "2020-08-17", "abstract": "The overarching goal of the present study is to evaluate the effect of a subanesthetic dose of ketamine 24-hour post-injection on resting state functional connectivity, cognitive control, and reward learning.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04239963", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "103a9ae5d78f6193943edddec11547d64ad07de49d3e6530e0ebb6c08179c034", "title": "A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder", "compound": "ketamine", "type": "phase_2", "institution": "Janssen Research & Development, LLC", "condition": "depression", "sample_size": 13, "status": "completed", "date": "2014-02-01", "abstract": "To evaluate if somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs) obtained with electroencephalography (EEG) and electromyography (EMG) can be used to detect changes in cortical plasticity in responders to a single IV infusion of ketamine as compared to non-responders.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01957410", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for major depressive disorder, human study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "0732328981bc8c0e512bc2855976880bd9c92107d1f37ded769d1f3c6a39d0d1", "title": "An Open Prospective Trial of IV Ketamine in Suicidal Adolescents", "compound": "ketamine", "type": "phase_2", "institution": "Nationwide Children's Hospital", "condition": "depression", "sample_size": 10, "status": "active", "date": "2013-06-01", "abstract": "1. Investigate the safety and effectiveness of a single dose of IV Ketamine for adolescents with suicidal ideation and depression. It is hypothesize that Ketamine will be well tolerated and significantly reduce depressive symptoms and suicidal ideation. 2.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02048423", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "IV ketamine for suicidal ideation and depression in adolescents.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "eac20696f734a650e20fbf4742e4adfe4ad24bf446a002288b3956852746bf82", "title": "Glutamatergic Modulation of Cocaine-related Deficits", "compound": "ketamine", "type": "phase_2", "institution": "New York State Psychiatric Institute", "condition": "addiction", "sample_size": 8, "status": "completed", "date": "2011-02-01", "abstract": "Cocaine dependence involves problematic neuroadaptations, such as heightened reactivity to cocaine cues, that may be responsive to pharmacological modulation of glutamatergic circuits.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01790490", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Addresses cocaine dependence, a form of addiction.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "e9d482be220b0db7febd59ce4ba30edbd6c0b28b9949d0703bf0265dc5f9f79a", "title": "Imaging SV2A in Mood Disorders", "compound": "ketamine", "type": "observational", "institution": "Yale University", "condition": "depression", "sample_size": 130, "status": "active", "date": "2016-04-01", "abstract": "This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02734602", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "ketamine for MDD and PTSD, human study", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "7d7c57698cbc76f0f23d7f3718a0cbf6986547c1a0cf997994c27ded80d01bd4", "title": "Sustained Ketamine Effectiveness for Suicidal Ideation", "compound": "ketamine", "type": "observational", "institution": "University Hospital, Montpellier", "condition": "depression", "sample_size": 128, "status": "completed", "date": "2023-12-01", "abstract": "As part of the usual clinical activity of the Emergency and Post-Emergency Psychiatric Department, IV ketamine is used to treat suicidal crises in depressed patients hospitalized as an add-on to the treatment of depression. This infusion can be repeated.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06806475", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for suicidal ideation in depressed patients.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "68c860aba1205e2c731c44efed6061ddf897b7bf6e805d46e0853a59f44b82d8", "title": "Trial of Ketamine and Lithium Therapy in Bipolar Depression", "compound": "ketamine", "type": "phase_2", "institution": "Yale University", "condition": "depression", "sample_size": 0, "status": "completed", "date": "2013-01-01", "abstract": "This study is looking at the safety and efficacy of combined ketamine and lithium therapy for treating patients with bipolar depression who are taking a mood stabilizer that is not working for them.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01768767", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Investigational treatment for bipolar depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "960507d3c39e9617b6c6b9fa99551e1d6b6d390e75d17d432ba30a6bb8332759", "title": "Esketamine on Postpartum Depression in Cesarean Section Women", "compound": "ketamine", "type": "observational", "institution": "Ailin Luo", "condition": "depression", "sample_size": 336, "status": "completed", "date": "2021-05-01", "abstract": "This study was to explore the preventive effect of esketamine on postpartum depression (PPD) in cesarean section, and to evaluate the safety of the drug", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04860661", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Esketamine for postpartum depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "8e2c685e2957da7fc71be95edd9bb9c523d37909bb108e011933906910abdcfd", "title": "Ketamine Safety in 2026: What Psychiatrists Need to Know About Monitoring Neurotoxicity and Clinical Guardrails", "compound": "ketamine", "type": "news", "institution": null, "condition": "other", "sample_size": null, "status": "other", "date": "2026-05-27", "abstract": "Although evidence supporting ketamine in treatment-resistant depression continues to grow, Brody noted that significantly less research exists for many other populations frequently encountered in practice.\u2026", "outcome_summary": null, "doi": null, "url": "https://www.psychiatrictimes.com/view/ketamine-safety-in-2026-what-psychiatrists-need-to-know-about-monitoring-neurotoxicity-and-clinical-guardrails", "source": "General News", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "e536e071c35039aa205bfe2cfccecc934e66e9772aa429173443750d086ae5f2", "title": "Structural imaging predictors of ketamine response in treatment-resistant depression: a machine learning approach", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": 99, "status": "published", "date": "2026-05-12", "abstract": "Translational Psychiatry volume 16, Article number: 330 (2026) Cite this article Save article 3097 Accesses 7 Altmetric Metrics details ## Abstract [...] Reprints and permissions ## About this article Check for updates.\u2026", "outcome_summary": "A machine-learning model using pre-treatment structural MRI data predicted antidepressant response to ketamine with 72.2% balanced accuracy in the discovery sample and 60.0% in external validation. Greater gray matter volume in frontal regions predicted response.", "doi": "s41398-026-04085-4", "url": "https://www.nature.com/articles/s41398-026-04085-4", "source": "General News", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Predicting ketamine response in treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } } ], "lsd": [ { "id": "047bc97473d13d08bb0cde7b3df446c9bfbd1b3fe2fde52b3ecb1aa4a04df158", "title": "LSD therapy: A few hundred meters from where it began.", "compound": "lsd", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-14", "abstract": "In Basel, only a few hundred meters from where LSD was first synthesized, we tested LSD-assisted therapy for major depression in a randomized trial comparing two high doses with two low doses, each paired with supportive psychotherapy.\u2026", "outcome_summary": null, "doi": "10.1016/j.medj.2026.101233", "url": "https://pubmed.ncbi.nlm.nih.gov/42600572/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "LSD-assisted therapy for major depression in a randomized trial.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "f52001e23c63180212d70c88f91201892e31747f88ee0ab55c912bcf520c684d", "title": "The impact of fluoxetine on the aversive effects of lysergic acid diethylamide.", "compound": "lsd", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-10", "abstract": "Serotonergic antidepressant history can reduce the subjective effects, including therapeutic efficacy, of a number of psychedelics. A related issue is the impact of traditional antidepressants with serotonergic action on the adverse effects of psychedelics. Becker et al.\u2026", "outcome_summary": null, "doi": "10.1037/pha0000876", "url": "https://pubmed.ncbi.nlm.nih.gov/42574097/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psychedelic drug interaction with antidepressant", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } } ], "dmt": [ { "id": "69eac3791ae4abe88e10566b9f0b8800ade197b98ca1d32a15ecb207ae997e4a", "title": "SPL026 With or Without SSRIs in Participants With MDD", "compound": "dmt", "type": "phase_1", "institution": "Small Pharma Ltd", "condition": "depression", "sample_size": 18, "status": "completed", "date": "2022-12-13", "abstract": "The main aim of the study is to test the safety and tolerability of single doses of SPL026 (N,N-dimethyltryptamine \\[DMT\\] fumarate, a psychedelic tryptamine) in patients currently taking a selective serotonin reuptake inhibitor (SSRI) for their depression, but for whom the SSRI is not fully relieving their depression.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05553691", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psychedelic treatment for major depressive disorder (MDD).", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "7a7c7f3f8a41a593b53d9e8a8cb3fa197b475ece95ad0a274b11fc617902b016", "title": "The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics", "compound": "dmt", "type": "phase_2", "institution": "GH Research PLC", "condition": "depression", "sample_size": null, "status": "active", "date": "2026-03-26", "abstract": "Known for its focus on 5-MeO-DMT (mebufotenin), a potent and naturally occurring psychedelic, GH Research is currently the subject of intense Wall Street scrutiny following the release of its pivotal Phase 2b clinical trial results.\u2026", "outcome_summary": "GH Research PLC's lead candidate, GH001, a 5-MeO-DMT based treatment, has shown promise in a Phase 2b trial for Treatment-Resistant Depression, offering near-instantaneous relief within a day of administration.", "doi": null, "url": "http://markets.chroniclejournal.com/chroniclejournal/article/finterra-2026-3-26-the-15-minute-breakthrough-a-deep-dive-into-gh-research-ghrs-and-the-future-of-rapid-acting-psychedelics", "source": "General News", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "5-MeO-DMT for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } } ], "ibogaine": [ { "id": "5f68909f5e3301a66a10a5fcf064590197fd0f30343586a994eb64f6932452f1", "title": "Trump signs order to fast track psychedelic drug research to treat veterans with PTSD", "compound": "ibogaine", "type": "regulatory", "institution": "Centers for Medicare & Medicaid Services", "condition": "PTSD", "sample_size": null, "status": "approved", "date": "2026-04-18", "abstract": "# Trump signs order to fast track psychedelic drug research to treat veterans with PTSD.\u2026", "outcome_summary": "President Trump signed an executive order to expedite research into ibogaine for treating PTSD and traumatic brain injuries in veterans, removing legal restrictions and establishing FDA protocols for its safe therapeutic use.", "doi": null, "url": "https://nypost.com/2026/04/18/us-news/trump-signs-order-to-fast-track-ibogaine-psychedelic-drug-research-to-treat-veterans-with-ptsd/", "source": "General News", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psychedelic research for veterans with PTSD and TBI.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } } ], "ayahuasca": [ { "id": "ebce9decc8243e4fab712eed02510d08bb4733f5fc49848d973dd2f0232014c9", "title": "Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial", "compound": "ayahuasca", "type": "phase_1", "institution": "University of Sao Paulo", "condition": "other", "sample_size": 15, "status": "recruiting", "date": "2026-07-01", "abstract": "Open label intervention with a single dose of ayahuasca in patients with psychogenic non-epileptic seizures (PNES)", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07747324", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Psychedelic treatment for a psychiatric condition (PNES).", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } } ], "other": [ { "id": "5ceb90c7de02dd66dac1a91216be1c7850741ae114f15d37af9c5e147b4ea5d9", "title": "Sex-sensitive serotonergic signaling in psychedelic pharmacology.", "compound": "other", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-10", "abstract": "Classic serotonergic psychedelics act primarily via 5-HT2A receptor agonism, yet their therapeutic effects and biological responses are heterogeneous.\u2026", "outcome_summary": null, "doi": "10.1016/j.tips.2026.07.006", "url": "https://pubmed.ncbi.nlm.nih.gov/42575820/", "source": "PubMed", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Mechanism of action of psychedelics in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "f869dd6b51ccb38289262551d1b4485da022267cd997af803f9b7e7efebdcdae", "title": "Correlates of Anxiety Associated With a Life-threatening Illness", "compound": "other", "type": "observational", "institution": "Resilient Pharmaceuticals", "condition": "anxiety", "sample_size": 12, "status": "completed", "date": "2015-11-07", "abstract": "The goal of this observational trial is to gather brain scan data on people undergoing MDMA-assisted therapy. The main question it aims to answer is: -How does brain activity change while completing an emotional regulation task in participants receiving MDMA-assisted therapy?\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02954562", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Observational trial on MDMA-assisted therapy for anxiety.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "31a0a9130f3856845ffdc093d36a173bdf0523c6c381ae41d5baf211d1082c63", "title": "MRI Studies of Emotion in Depression", "compound": "other", "type": "observational", "institution": "Icahn School of Medicine at Mount Sinai", "condition": "depression", "sample_size": 135, "status": "completed", "date": "2011-07-15", "abstract": "The purpose of this study is to research the effects of ketamine on brain function in patients with Major Depressive Disorder (MDD). This study is an ancillary MRI neuroimaging study being conducted in patients with MDD who are enrolled in a separate clinical trial.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02429011", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "MRI neuroimaging of ketamine for depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "1f3c6d24d2512adf0db4930728f2f756de854204212dae5320ba8a9db50e078a", "title": "Study of NMDA Antagonists and Neuropathic Pain", "compound": "other", "type": "phase_2", "institution": "University Hospital, Clermont-Ferrand", "condition": "other", "sample_size": 7, "status": "completed", "date": "2012-05-01", "abstract": "The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01602185", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Investigational treatment for chronic neuropathic pain.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "bc9a16b5c30efddc91508111ee80e5f02707fc727aa499bfd513ea3a17c40b45", "title": "Opiate Suicide Study in Patients With Major Depression", "compound": "other", "type": "phase_3", "institution": "Stanford University", "condition": "depression", "sample_size": 50, "status": "completed", "date": "2020-08-01", "abstract": "To explore whether intravenous ketamine followed by buprenorphine produces more rapid and sustained anti-suicidal effects than ketamine followed by placebo, investigators will conduct a single study that will take approximately 2.5 years to complete.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04116528", "source": "ClinicalTrials.gov", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression and suicidal ideation.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "082c1ee084be2f0f5d0bd0dda667ca6c755cd218fd706268babf6c95846730ba", "title": "Plant Medicine Influencer Culture on Social Media", "compound": "other", "type": "news", "institution": null, "condition": "other", "sample_size": null, "status": "other", "date": "2026-08-10", "abstract": "

If plants could speak, who would they elect to spread their message to the world?

In 2020, the rise of social media plant medicine influencers came on the heels of leading cultural figures sharing their psychedelic experiences in popular media, including the New York Times bestselling book, How To Change Your Mind by Michael Pollan, as well as the Netflix documentaries, Have a Good Trip and Fantastic Fungi.

After decades of dormancy tied to the declaration of the \u201cWar On Drugs\u201d (1971) and the scheduling of numerous psychedelic compounds under the Controlled Substances Act in 1970, researchers at high-profile institutions like University of New Mexico and Imperial College London renewed clinical investigation of various psychedelics such as DMT and psilocybin in the 1990s and early 2000s, gradually opening the door to a renewed public dialogue around psychedelic compounds and the plants and fungi that harbor them. 

“Social media has democratized access to plant medicine information and education unlike anything in history.”

Coupled with the rise of psychedelic biotech companies like Atai and Compass Pathways and increasing media coverage of the emerging \u201cPsychedelic Renaissance\u201d circa 2020, the taboo around speaking publicly about psychedelics was lifted at the exact moment when influencers around the world were poised to take advantage of their large social media followings across various platforms.\u2026", "outcome_summary": "The article discusses the rise of social media influencers in the plant medicine space, coinciding with increased public interest in psychedelics and renewed clinical research. It highlights how social media has democratized access to information but also risks decontextualizing and commodifying ancient knowledge and psychedelic experiences.", "doi": null, "url": "https://chacruna.net/plant-medicine-influencer-culture-on-social-media/", "source": "Chacruna Institute", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Discusses social media's role in psychedelic culture and research.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "73813f790e7dc89313edf7ecd21cc0830638d80ce01ff2aef1887a61f1dfdd1e", "title": "AOC, Other Members of Congress Tout Psychedelic Benefits as Research Amendments Advance", "compound": "other", "type": "news", "institution": "Department of Defense", "condition": "other", "sample_size": null, "status": "active", "date": "2026-08-08", "abstract": "

In this week’s psychedelic policy briefing, investigative journalist Jack Gorsline unpacks a wave of state and federal initiatives aimed at expanding alternative therapies for veterans and those battling addiction.\u2026", "outcome_summary": "Bipartisan lawmakers are leveraging the National Defense Authorization Act to extend military clinical trials for substances like psilocybin and MDMA. The Department of Veterans Affairs is also pushing to expedite treatment research for PTSD. A Louisiana law uses opioid settlement funds for a pilot program targeting substance abuse and treatment-resistant mental health conditions.", "doi": null, "url": "https://www.lucid.news/psychedelic-policy-briefing/", "source": "Lucid News", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Congressional action and VA research on psychedelics for PTSD and mental health.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } }, { "id": "302c1761829c8d46d07a7e3ee0bc872c74690686c28ae2d45a337063512b559c", "title": "Trump Signs Executive Order Endorsing Psychedelic Psilocybin and Ibogaine; Asks 'Can I Have Some, Please?'", "compound": "other", "type": "regulatory", "institution": null, "condition": "other", "sample_size": null, "status": "approved", "date": "2026-04-19", "abstract": "# Trump Signs Executive Order Endorsing Psychedelic Psilocybin and Ibogaine; Asks 'Can I Have Some, Please?'. ## President Trump signs an executive order to expedite the review and funding of psychedelic drugs for mental health treatment.\u2026", "outcome_summary": "President Trump signed an executive order directing federal agencies to expedite the review and funding of psychedelic drugs, including psilocybin and ibogaine, for serious mental illness treatments. The order allocates $50 million for state-level research programs and instructs the FDA to issue National Priority Vouchers for qualifying psychedelic compounds.", "doi": null, "url": "https://www.ibtimes.co.uk/trump-psychedelic-drug-research-mental-illness-1792468", "source": "General News", "first_seen": "2026-08-17", "relevance": { "relevant": true, "reason": "Regulatory and policy news on psilocybin and ibogaine for mental illness.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-17" } } ] } }